Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncological and Immunological Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for c-Cbl/CBL drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | c-Cbl/CBL Wild-Type & Mutant Proteins High purity (>95%), Endotoxin controlled. Sequence Verified. Intracellular domain / Full-length constructs. |
View CBL Products |
| Gene Delivery | c-Cbl/CBL Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View CBL Products |
| Benchmark Ab | Anti-c-Cbl/CBL Recombinant Antibody High-affinity positive control clone for immunoprecipitation and Western Blot validation. |
View CBL Products |
| Validator | c-Cbl/CBL siRNA Set Target-specific knockdown verification in cell-based functional assays. |
View CBL Products |
| Related Target A | CBL-B Highly homologous E3 ligase. Essential counter-screening target for selectivity profiling in immunotherapy programs. |
View CBL-B Products |
| Related Target B | EGFR Primary downstream RTK substrate of c-Cbl ubiquitination. Crucial for functional degradation assays. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| E3 Ligase Autoubiquitination Activity | Recombinant c-Cbl proteins with verified enzymatic activity, high purity (>95%), and low endotoxin. |
| Selectivity Screening (CBL vs. CBL-B) | Matched active protein panels for both c-Cbl and CBL-B to ensure off-target safety profiling. |
| Lack of Controls | Clinical-grade benchmark antibodies and validated siRNA sequences included for assay baseline calibration. |
| False Positives in PPI Assays | Sequence-verified TKB and RING domain truncations to map exact binding sites and eliminate non-specific interactions. |
Live c-Cbl/CBL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for c-Cbl/CBL therapeutics is intensifying, with major players shifting focus from traditional multi-kinase inhibitors to targeted E3 ligase modulators and PROTACs. As first-generation therapies targeting mutant CBL in myeloid malignancies reach the clinic, the next wave of R&D is targeting wild-type c-Cbl to overcome receptor tyrosine kinase (RTK) resistance pathways in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Novartis, Incyte | Myeloproliferative Neoplasms (MPN), JMML | Selectivity Assay (Need Mutant vs WT Proteins to avoid systemic toxicity) |
| PROTAC / Glue E3 Recruiters | Arvinas, Kymera Therapeutics | Non-Small Cell Lung Cancer (NSCLC), Solid Tumors | TKB/RING Domain Binding Assays (Need high-purity truncation proteins) |
| Combination Therapies | AstraZeneca, Roche | EGFR-mutant / MET-amplified Cancers | Substrate Ubiquitination Assays (Need functional RTK partner proteins) |